Trial Profile
Safety and efficacy study of glucarpidase for delayed clearance of methotrexate after administration of high-dose methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2021
Price :
$35
*
At a glance
- Drugs Glucarpidase (Primary)
- Indications Chemotherapy-induced damage
- Focus Pharmacokinetics
- Acronyms CPG2-PII
- 28 Sep 2021 According to BTG Specialty Pharmaceuticals media release, Ohara Pharmaceutical Co., Ltd. has obtained marketing authorization for glucarpidase from Japan's Ministry of Health, Labour and Welfare as a therapeutic agent for "detoxication in case of delayed methotrexate elimination with methotrexate-leucovorin rescue therapy," based on the efficacy and safety results of this study.
- 02 Jul 2018 Status changed from recruiting to completed.
- 07 Jun 2016 Results (n=13) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology